Tele2 AB Q4 Underlying EBITDAaL Increases; End-user Service Revenue Up 2% Organically

East Japan Railway Company 9-month Loss Narrows – Quick Facts

East Japan Railway Company (EJPRF.PK,EJPRY.PK) reported a loss to owners of parent of 83.75 billion yen for the nine-month period ended December 31, 2021 compared to a loss of 294.59 billion yen, prior year. Basic loss per share was 222.01 yen compared to a loss of 780.91 yen.

For the nine month period, operating revenues were 1.48 trillion yen, up 13.5 percent from last year.

For the year ending March 31, 2022, the company estimates: basic loss per share of 424.13 yen, and operating revenues of 2.06 trillion yen.

T-Mobile To Fire Unvaccinated Employees After April

Telecommunication company, T-Mobile US Inc. (TMUS) has recently handed out a memo to the employees which will see the unvaccinated employees losing their jobs in the company after April 2.

The company published the memo as an internal blog named The T-MO Report on Friday which was shared to all the employees by the HR team. The blog also cited the supreme court which also rendered the “regular testing” method for unvaccinated people, useless. The memo said, “Employees who have not yet taken action to receive their first dose and upload proof by February 21 will be placed on unpaid leave. Affected employees who do not become fully vaccinated … by April 2 will be separated from T-Mobile.”

“We understand that this is a deeply personal decision for some employees but we believe that taking this step will put us in the best position to protect our T-Mobile community,” the company added.

However, the rules do not apply to the technicians and in-store retail employees. On Saturday, the company said, “we are requiring office workers (with a limited exception for certain roles, locations and legally mandated accommodations and exemptions) to be fully vaccinated by April 2.” The company presently allows only vaccinated employees in the office who can be identified with the help of their badges which are called Magents Pass

The government has moved away from its stern vaccine mandates and has already suggested that companies with more than 100 employees do not need to get their workers vaccinated if they can test their employees.

Trevor Noah: Trump Is America’s Relentless Ex

“And like many exes, he really wants a second chance. But instead of promising to do better next time, he’s threatening to do even worse,” Noah said.

By Trish Bendix

Citrix Systems Inc Q4 Profit Decreases, but beats estimates

Citrix Systems Inc (CTXS) revealed earnings for fourth quarter that decreased from last year but beat the Street estimates.

The company’s earnings came in at $102.90 million, or $0.81 per share. This compares with $112.09 million, or $0.89 per share, in last year’s fourth quarter.

Excluding items, Citrix Systems Inc reported adjusted earnings of $186 million or $1.47 per share for the period.

Analysts on average had expected the company to earn $1.08 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

The company’s revenue for the quarter rose 5.1% to $850.85 million from $809.66 million last year.

Citrix Systems Inc earnings at a glance (GAAP) :

-Earnings (Q4): $102.90 Mln. vs. $112.09 Mln. last year.
-EPS (Q4): $0.81 vs. $0.89 last year.
-Analyst Estimates: $1.08
-Revenue (Q4): $850.85 Mln vs. $809.66 Mln last year.

Why Ionis Pharma Stock Falling In Pre-market?

Pfizer Inc. (PFE) and Ionis Pharmaceuticals, Inc. (IONS) announced the discontinuation of the Pfizer-led clinical development program for vupanorsen, an investigational antisense therapy. Also, Pfizer will return development rights to vupanorsen to Ionis.

Pfizer made the decision after a review of data from the phase 2b double-blind, placebo-controlled, dose-ranging, 8-arm parallel-group study of vupanorsen in statin-treated participants with dyslipidemia. The company said the the magnitude of non-high density lipoprotein cholesterol and triglycerides reduction observed did not support continuation of the clinical development program for cardiovascular risk reduction or severe hypertriglyceridemia.

Shares of Ionis Pharmaceuticals were down 8% in pre-market trade on Monday.

Tele2 AB Q4 Underlying EBITDAaL Increases; End-user Service Revenue Up 2% Organically

Tele2 AB (TLTZF.PK,TLTZY.PK) reported fourth quarter underlying EBITDAaL of 2.4 billion Swedish kronor, an increase of 1% organically compared to prior year driven by end-user service revenue growth and cost savings related to the Business Transformation Program, partly offset by higher commercial spending. End-user service revenue was 4.9 billion Swedish kronor, up 2% on an organic basis due to strong performance in the Baltics and slight tailwind from roaming.

Fourth quarter net profit from continuing operations declined to 910 million Swedish kronor from 4.48 billion Swedish kronor, prior year. Earnings per share was 1.31 kronor compared to 6.46 kronor.

Fourth quarter revenue increased to 7.03 billion kronor from 6.88 billion kronor, last year. Total revenue increased by 2% on an organic basis.

For full-year 2022, the company projects: low single-digit growth of end-user service revenue; and mid single-digit growth of underlying EBITDAaL.

For mid-term, the company continues to expect: low single-digit growth of end-user service revenue; and mid single-digit growth of underlying EBITDAaL.

For fiscal 2021, the Board of Tele2 AB has decided to recommend to the AGM that an ordinary dividend of 6.75 Swedish kronor in total be paid per ordinary A and B share in two tranches in May and October, 2022.